Teva Pharmaceutical Industries (TEVA) Revenue (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Revenue for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 0.81% year-over-year to $4.1 billion; the trailing twelve-month figure through Jun 2026 stood at $17.3 billion (up 13.18% YoY), and the FY2025 full-year result was $17.3 billion, up 4.32% from the prior year.
• Revenue rose to $4.1 billion in Q2 2026 per TEVA's latest filing, from $4.0 billion in the prior quarter.
• Across five years, Revenue topped out at $4.7 billion in Q4 2025 and bottomed at $2.9 billion in Q4 2024.
• Historically, Revenue has averaged $4.0 billion across 5 years, with a median of $3.9 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Revenue sank 34.93% in 2024, then surged 62.45% in 2025.
• Over 5 years, Revenue stood at $3.9 billion in 2022, then advanced by 14.75% to $4.5 billion in 2023, then tumbled by 34.93% to $2.9 billion in 2024, then jumped by 62.45% to $4.7 billion in 2025, then retreated by 12.08% to $4.1 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $4.1 billion, $4.0 billion, and $4.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.